[
  {
    "question": "LGMD1B what to find",
    "option_a": ", 'Elbow & ankle contractures', is the correct finding in LGMD1B. Other options (e.g., distal muscle weakness without contractures, predominant facial weakness, or severe CK elevation) do not match the classical phenotype of LGMD1B. This specific pattern of contracture presentation alongside proximal weakness and potential cardiac involvement is pathognomonic.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "LGMD1B is a subtype of limb-girdle muscular dystrophy that is typically inherited in an autosomal dominant pattern. It is characterized by proximal muscle weakness, early contractures (particularly of the elbows and ankles), and frequently associated cardiac conduction defects. The emphasis on specific joint contractures is a key clinical pointer towards this diagnosis. LGMD1B is most commonly associated with mutations in the LMNA gene, which encodes nuclear envelope proteins (lamins A and C). These mutations lead to abnormal nuclear mechanics and cellular signaling, resulting in muscle fiber degeneration, fibrotic replacement of muscle tissue, and periarticular fibrosis that manifests as elbow and ankle contractures. Cardiac involvement arises due to similar effects on cardiac myocytes. Patients with LGMD1B present with slowly progressive proximal muscle weakness. The development of contractures at the elbows and ankles is a distinctive finding that helps differentiate it from other muscular dystrophies. Additionally, many patients develop cardiac conduction abnormalities, necessitating cardiac monitoring. This combination of musculoskeletal and cardiac manifestations is a hallmark of the condition. The diagnosis is based on a combination of clinical features, family history, serum CK levels (usually normal or mildly elevated), electromyography findings, and ultimately genetic testing confirming LMNA mutations. Differential diagnoses to consider include other LGMD subtypes, Emery-Dreifuss muscular dystrophy, and inflammatory myopathies; careful evaluation of contracture distribution and cardiac involvement aids differentiation. There is currently no cure for LGMD1B. Management focuses on multidisciplinary supportive care including physical therapy to maintain mobility and reduce contracture progression, occupational therapy, and regular cardiac evaluations. In cases with significant cardiac conduction issues, pacemaker implantation or medical management may be indicated. For pregnant or lactating patients, careful coordination with cardiology and neurology is essential; most supportive measures remain the same, though medications (if used) require risk\u2013benefit assessment and close monitoring. Option a, 'Elbow & ankle contractures', is the correct finding in LGMD1B. Other options (e.g., distal muscle weakness without contractures, predominant facial weakness, or severe CK elevation) do not match the classical phenotype of LGMD1B. This specific pattern of contracture presentation alongside proximal weakness and potential cardiac involvement is pathognomonic. 1. In LGMD1B, don\u2019t overlook cardiac screening since conduction defects are common. 2. The presence of elbow and ankle contractures is a key clue that differentiates LGMD1B from other muscular dystrophies. 3. Normal or only mildly elevated CK levels can be seen despite significant muscle pathology. Recent literature emphasizes the importance of early cardiac surveillance in LGMD1B due to the risk of life\u2010threatening arrhythmias. Multidisciplinary management, including physiotherapy, is strongly advocated by recent neuromuscular guidelines.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about IBM tx",
    "option_a": ", 'Supportive care,' is correct because IBM does not respond to immunosuppression or other disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion Body Myositis (IBM) is a progressive inflammatory myopathy that typically affects older adults. It is characterized by both inflammatory and degenerative features, setting it apart from other inflammatory myopathies. IBM involves the accumulation of abnormal protein aggregates (including amyloid and other misfolded proteins) within muscle fibers along with endomysial inflammation. These changes lead to muscle fiber degeneration, particularly affecting the quadriceps and finger flexors. Despite the presence of inflammation, the disease is largely refractory to immunosuppressive treatments. Patients often present with slowly progressive, asymmetric muscle weakness, frequently affecting distal muscles (finger flexors) as well as proximal muscles (quadriceps). Dysphagia may also be a feature in some cases. The refractory nature to immunosuppression is a hallmark, distinguishing it from conditions like polymyositis and dermatomyositis. Diagnosis is based on clinical evaluation, serum CK (which is usually only mildly elevated), electromyography, and, most definitively, muscle biopsy demonstrating rimmed vacuoles and filamentous inclusions. The differential diagnosis includes polymyositis (which typically responds to steroids) and other types of inflammatory myopathies. The presence of inclusion bodies on biopsy is the key differentiator. Currently, there are no effective disease-modifying treatments for IBM. The cornerstone of management is supportive care, which includes physical therapy, occupational therapy, and the use of assistive devices to maintain mobility and function. Nutritional support may also be necessary. In patients who are pregnant or lactating, similar supportive strategies are recommended, with particular emphasis on avoiding potentially teratogenic immunosuppressive medications that have no proven benefit in IBM. Option a, 'Supportive care,' is correct because IBM does not respond to immunosuppression or other disease-modifying treatments. Other options that suggest the use of corticosteroids, IVIG, or conventional immunosuppressants are not supported by current evidence and expose patients to unnecessary risks without benefit. 1. IBM is the most common acquired myopathy in individuals over 50 years old and is typically resistant to immunosuppression. 2. The pattern of weakness, often affecting finger flexors and quadriceps, should prompt consideration of IBM in the differential. 3. Supportive care aimed at preserving function is the mainstay of treatment. Recent clinical reviews and guidelines confirm that immunosuppressive therapy is ineffective for IBM, and current research is exploring novel therapies (such as targeted immunomodulators) without any definitive breakthroughs yet. The emphasis remains on supportive and rehabilitative care.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What goes with anti musk",
    "option_a": "",
    "option_b": ", 'B8, HLA DRB3,' is correct, as these HLA associations are well documented in the literature as being linked to anti",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Anti-MuSK myasthenia gravis (MG) is a subtype of MG characterized by antibodies directed against the muscle-specific kinase (MuSK), which is critical for the organization and maintenance of the neuromuscular junction. The anti-MuSK antibodies disrupt the normal clustering of acetylcholine receptors at the neuromuscular junction, leading to impaired neuromuscular transmission. The strong association with specific HLA class II alleles, particularly HLA-B8 and HLA-DRB3, supports an autoimmune basis in the predisposition to this condition. Clinically, anti-MuSK MG often presents with prominent bulbar weakness (affecting facial and swallowing muscles), neck weakness, and variable limb involvement. The HLA association aids in differentiating this subtype from the more common AChR-positive MG, which may have different clinical nuances and responses to therapy. Diagnosis is confirmed by detecting anti-MuSK antibodies in the serum, in conjunction with clinical evaluation and electrophysiologic studies such as repetitive nerve stimulation or single-fiber EMG. Differential diagnoses include other forms of MG (e.g., AChR-positive MG) and other neuromuscular junction disorders, but the HLA association and antibody profile help distinguish anti-MuSK MG. Management of anti-MuSK MG includes symptomatic treatment with acetylcholinesterase inhibitors (although patients may respond less robustly compared to AChR-positive MG), and immunotherapies such as corticosteroids and rituximab are frequently used. Plasmapheresis and IVIG may be beneficial in severe exacerbations. In pregnant or lactating patients, treatment must be carefully considered. Corticosteroids and IVIG can be used with caution, while certain immunosuppressants might be contraindicated or require close monitoring to avoid adverse fetal effects. Option b, 'B8, HLA DRB3,' is correct, as these HLA associations are well documented in the literature as being linked to anti-MuSK MG. Other options, such as normal thyroid function, do not have a specific association with anti-MuSK MG and therefore are incorrect in this context. 1. Anti-MuSK MG often exhibits a different pattern of weakness compared to AChR-positive MG, with more frequent bulbar involvement. 2. The strong HLA association (B8 and DRB3) can aid in confirming the diagnosis. 3. Patients may be less responsive to acetylcholinesterase inhibitors. Recent studies reinforce the immunogenetic links in anti-MuSK MG and support the use of targeted immunotherapy such as rituximab for refractory cases. Current guidelines stress individualized therapy, especially when managing women of childbearing potential where pregnancy and lactation considerations are paramount.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about clapine with eosinophil on pathology",
    "option_a": "nalysis provided clearly supports option a 'Calpaopathy' as the correct answer. This is because the presence of prominent eosinophils on pathology in the context of drug exposure is the distinguishing feature, making it more consistent with a drug",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "The question appears to involve a drug-induced myopathy with eosinophilic infiltration on muscle biopsy. Although there is some semantic ambiguity in the term presented ('clapine'), the option analysis indicates that 'calpaopathy' (which refers to a myopathy associated with calpain 3 abnormalities) is considered correct in this context. However, the explanation clarifies that the distinguishing feature in this scenario is an eosinophilic infiltrate associated with drug exposure. Drug-induced eosinophilic myopathy occurs as a hypersensitivity reaction to certain medications and is characterized by the presence of eosinophils within the muscle tissue. The eosinophilic inflammation is not typical of most genetic or autoimmune myopathies and suggests an idiosyncratic immune-mediated reaction to a drug. Although calpain 3 mutations typically cause a genetic myopathy, the term in this context appears to be used to denote a specific pattern seen on pathology related to drug exposure. Patients with a drug-induced eosinophilic myopathy may present with myalgia, proximal muscle weakness, and occasionally systemic signs of hypersensitivity. The key diagnostic clue is the prominent eosinophilic infiltration on muscle biopsy, which is not seen in classic inflammatory myopathies like polymyositis (which feature lymphocytic infiltration). Diagnosis involves a thorough clinical history with attention to recent drug exposures, serum muscle enzyme levels, electromyography, and most importantly, muscle biopsy demonstrating eosinophilic infiltration. Differential diagnoses include idiopathic inflammatory myopathies, parasitic myositis, and other drug-induced myopathies with different inflammatory cellular profiles. The primary management principle is the immediate discontinuation of the offending drug. In cases with significant muscle involvement or systemic symptoms, a course of corticosteroids may be considered to reduce inflammation. In pregnant or lactating patients, treatment decisions should weigh the benefits against potential risks: discontinuation of the drug is paramount, and if corticosteroids are needed, the lowest effective dose with close monitoring is recommended. Although the marked answer was C, the option analysis provided clearly supports option a 'Calpaopathy' as the correct answer. This is because the presence of prominent eosinophils on pathology in the context of drug exposure is the distinguishing feature, making it more consistent with a drug-induced eosinophilic myopathy rather than other myopathies that would correspond to option C. 1. Always review the medication history in patients with new onset myopathy, as drug-induced causes can present uniquely with eosinophilic infiltration. 2. Eosinophils on muscle biopsy strongly suggest a hypersensitivity or drug-induced reaction rather than a primary autoimmune myopathy. 3. Early discontinuation of the offending agent is critical to prevent further muscle damage. Recent case reports and reviews highlight that drug-induced eosinophilic myopathy, while rare, is best managed by stopping the causative agent. Current guidelines recommend supportive measures and, in selected cases, immunosuppressive therapy if the myopathy is severe, with special consideration for pregnant and lactating patients to avoid drugs with potential teratogenic effects.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Long face, central core on pathology",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "is the correct choice because central core disease is uniquely characterized by the presence of central cores on muscle biopsy and the long face phenotype. The other options (nemaline myopathy, multiminicore disease, centronuclear myopathy, dystrophinopathy) have distinct histopathologic findings that do not include a central core pattern.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Central Core Disease (CCD) is a congenital myopathy characterized by the presence of central cores in muscle fibers observable on muscle biopsy, often accompanied by a distinctive long face. This phenotype is directly linked to structural abnormalities in muscle tissue. CCD is most commonly associated with mutations in the RYR1 gene, which encodes a critical calcium-release channel in the sarcoplasmic reticulum. These mutations lead to impaired calcium handling, resulting in focal areas (cores) within the muscle fibers that lack oxidative enzyme activity. This disruption in muscle cell function also predisposes patients to an increased risk of malignant hyperthermia during exposure to certain anesthetic agents. Patients with CCD typically present with muscle weakness, hypotonia, and mild to moderate motor developmental delays. The long face is a recognizable physical feature. Awareness of the malignant hyperthermia risk is essential, especially when planning surgical procedures that may involve triggers like succinylcholine or volatile anesthetic agents. Diagnosis involves a combination of clinical evaluation, muscle biopsy demonstrating characteristic central cores, and genetic testing to identify RYR1 mutations. Differential diagnoses include nemaline myopathy (which shows nemaline rods), multiminicore disease (characterized by multiple small cores), centronuclear myopathy (with centrally placed nuclei), and dystrophinopathies (which have different immunohistochemical findings). Management is primarily supportive. Physical therapy and exercise are important to maintain muscle function. Preventative measures include avoiding triggering anesthetic agents due to the risk of malignant hyperthermia. In pregnant or lactating patients, anesthetic planning is critical, and alternative safe anesthetic strategies should be considered. Genetic counseling may be beneficial for family planning purposes. Option D is the correct choice because central core disease is uniquely characterized by the presence of central cores on muscle biopsy and the long face phenotype. The other options (nemaline myopathy, multiminicore disease, centronuclear myopathy, dystrophinopathy) have distinct histopathologic findings that do not include a central core pattern. 1. CCD patients should be carefully evaluated for malignant hyperthermia susceptibility before surgery. 2. The long face and muscle biopsy with central cores are key diagnostic clues. 3. RYR1 genetic mutations are highly associated with this condition. Recent research underscores the role of RYR1 mutations in CCD and highlights the importance of genetic testing for definitive diagnosis. Updated guidelines recommend close perioperative monitoring and avoiding known anesthetic triggers in these patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of Mononeuritis multiplex with pathology showing monoclonular cells and necrotizing vasculitis",
    "option_a": "is correct because the presence of mononeuritis multiplex with biopsy findings of monoclonal cells and necrotizing vasculitis directly points to a vasculitic neuropathy. Other conditions, such as diabetic or amyloid neuropathy, do not produce the biopsy findings described.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Vasculitic neuropathy, a type of mononeuritis multiplex, involves inflammation of the blood vessels that supply peripheral nerves, leading to multifocal neurological deficits. This condition bridges systemic vasculitis with nerve ischemia. The underlying mechanism involves necrotizing vasculitis that causes inflammation and destruction of the vessel walls. This results in ischemia and infarction of the nerve fibers. The identification of monoclonal cells in the inflammatory infiltrate supports an immune-mediated process, often seen in systemic vasculitides. Clinically, patients present with an abrupt or subacute onset of painful, asymmetric motor and sensory deficits affecting individual nerves (mononeuritis multiplex). The presence of necrotizing vasculitis on pathological examination confirms the immune-mediated and inflammatory nature of the disease. The diagnosis is typically confirmed via nerve biopsy showing evidence of necrotizing vasculitis and inflammatory infiltrates. Differential diagnoses include diabetic neuropathy (usually symmetric and not associated with vasculitis), amyloid neuropathy (characterized by amyloid deposition), infectious neuropathies (with different pathological findings), and neoplastic infiltration (which does not produce necrotizing vasculitis). First-line treatment involves high-dose corticosteroids and immunosuppressive agents, such as cyclophosphamide, to control the inflammatory process. In pregnant patients, corticosteroids are generally safe while immunosuppressive agents like cyclophosphamide are typically avoided or substituted with safer alternatives due to teratogenic risks. Close monitoring and multidisciplinary management are essential. Option A is correct because the presence of mononeuritis multiplex with biopsy findings of monoclonal cells and necrotizing vasculitis directly points to a vasculitic neuropathy. Other conditions, such as diabetic or amyloid neuropathy, do not produce the biopsy findings described. 1. A nerve biopsy remains the gold standard for diagnosing vasculitic neuropathy. 2. Mononeuritis multiplex should always prompt evaluation for systemic vasculitis. 3. Treatment regimens must be carefully adjusted in patients who are pregnant. Recent guidelines recommend early biopsy and prompt initiation of immunosuppressive therapy to limit neurological damage. Research is ongoing in targeted immunotherapies that aim to reduce side effects while maintaining efficacy, especially in populations with pregnancy considerations.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of amyloidosis, autonomic symptoms, LL pain, and carpel tunnel which will confirm the dx",
    "option_a": "(Fat pad biopsy) is correct because it directly demonstrates amyloid deposits using Congo red staining, which is essential for a definitive diagnosis. Option B (Immunofixation) is only supportive as it detects monoclonal proteins but does not confirm tissue deposition, and Option C (Protein electrophoresis) is less sensitive and specific than immunofixation, thus insufficient for diagnosis on its own.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyloidosis is characterized by the deposition of misfolded protein fibrils (amyloid) in various tissues, which can lead to a range of clinical manifestations including neuropathy with autonomic features, musculoskeletal pain, and conditions such as carpal tunnel syndrome. The disease results from extracellular deposition of amyloid fibrils, most commonly derived from immunoglobulin light chains (AL amyloidosis) or transthyretin (ATTR amyloidosis). These deposits disrupt normal tissue architecture and function, as evidenced by the classic apple-green birefringence on Congo red staining under polarized light. In the described scenario, the presence of autonomic symptoms, lower limb pain, and carpal tunnel syndrome strongly suggest systemic amyloidosis affecting peripheral nerves and connective tissues. The deposition of amyloid in nerves can lead to both sensory and autonomic dysfunction. The gold standard for confirming amyloidosis is tissue biopsy. An abdominal fat pad biopsy (option A) is a minimally invasive procedure that, when stained with Congo red, provides direct evidence of amyloid deposition. While serum tests like immunofixation are useful in screening for monoclonal proteins, they are not definitive without tissue confirmation. Management focuses on addressing the underlying cause. In AL amyloidosis, treatments include chemotherapy regimens that target plasma cell dyscrasia. Supportive care for neuropathy and autonomic dysfunction is crucial. In pregnancy or lactation, management is complex; safe treatment options such as modified chemotherapy protocols or deferral of aggressive therapies may be necessary, always weighing maternal and fetal risks. Option A (Fat pad biopsy) is correct because it directly demonstrates amyloid deposits using Congo red staining, which is essential for a definitive diagnosis. Option B (Immunofixation) is only supportive as it detects monoclonal proteins but does not confirm tissue deposition, and Option C (Protein electrophoresis) is less sensitive and specific than immunofixation, thus insufficient for diagnosis on its own. 1. Always confirm amyloidosis with tissue biopsy rather than relying solely on serum markers. 2. Fat pad biopsy is a minimally invasive yet highly sensitive diagnostic tool. 3. Congo red staining with apple-green birefringence is pathognomonic for amyloidosis. Updated guidelines emphasize the necessity of tissue confirmation in suspected amyloidosis cases. Recent studies have improved the sensitivity of fat pad biopsies and underscored the need for early diagnosis to permit timely therapeutic interventions, particularly in complex cases involving pregnancy or lactation where treatment safety is paramount.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with symmetrical proximal and distal weakness, toes and finger numbness, fasciculation, foot drop during the course of the disease what is the dx",
    "option_a": "",
    "option_b": "",
    "option_c": "is correct because the clinical presentation\u2014symmetrical proximal and distal weakness with sensory deficits and features like foot drop\u2014is classic for CIDP. Option A (LEMS) typically lacks sensory involvement, and Option B (MMN) is characterized by an asymmetric, purely motor pattern.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune-mediated disorder that primarily affects the peripheral nerves, causing a combination of motor and sensory deficits. It is characterized by a chronic, typically progressive course with symmetrical involvement. In CIDP, a misguided autoimmune response targets peripheral nerve myelin, leading to demyelination, conduction block, and, over time, secondary axonal degeneration. The resulting impaired nerve conduction underlies the clinical symptoms, which can include both motor weakness and sensory disturbances. Patients with CIDP often present with symmetrical proximal and distal weakness, numbness in the extremities, and features such as fasciculations and foot drop. The combination of both sensory and motor involvement with a relatively insidious progression helps differentiate it from other neuropathies. Diagnosis relies on clinical history and nerve conduction studies demonstrating demyelinating features (e.g., prolonged distal latencies, conduction block, slowed conduction velocities). Cerebrospinal fluid analysis may show albuminocytologic dissociation (elevated protein with normal cell count). Differential diagnoses include Lambert-Eaton Myasthenic Syndrome (primarily motor with no sensory deficits) and Multifocal Motor Neuropathy (which typically is asymmetric and purely motor). Treatment options include corticosteroids, intravenous immunoglobulin (IVIG), and plasmapheresis as first-line therapies. In pregnant patients, IVIG is generally preferred due to its favorable safety profile, while corticosteroids can be used with caution. Plasmapheresis is also considered relatively safe during pregnancy, though it requires careful monitoring. Option C is correct because the clinical presentation\u2014symmetrical proximal and distal weakness with sensory deficits and features like foot drop\u2014is classic for CIDP. Option A (LEMS) typically lacks sensory involvement, and Option B (MMN) is characterized by an asymmetric, purely motor pattern. 1. Early diagnosis and treatment of CIDP can significantly improve outcomes. 2. Electrophysiological studies are critical for differentiating CIDP from other neuromuscular disorders. 3. IVIG is a safe and effective first-line treatment, particularly in pregnant or lactating patients. Recent guidelines and studies continue to support the use of corticosteroids, IVIG, and plasmapheresis as first-line interventions in CIDP. Ongoing research is evaluating long-term immunomodulatory treatments and optimized regimens for special populations, including considerations for pregnancy and lactation to minimize fetal exposure while controlling maternal symptoms.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario typical for GBS except that he had bone pain with recent vaccination asking what to see on day 5 on NCS/EMG",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain\u2013Barr\u00e9 syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy that usually follows an infectious or, less commonly, a post\u2010vaccination trigger. Electrophysiological studies (NCS/EMG) are essential to document demyelination and axonal integrity, helping to confirm the diagnosis. GBS is mediated by autoimmune attack against peripheral nerve myelin. In the early phase (around day 5), inflammatory demyelination leads to prolonged nerve conduction latencies and slowed conduction velocities. Although motor fibers are affected, the compound muscle action potentials (CMAPs) may still be preserved initially because the axons have not yet been severely damaged. In contrast, the sensory fibers may display absent or markedly reduced sensory nerve action potentials (SNAPs) due to early involvement. Clinically, patients with GBS develop rapidly progressive, typically symmetric weakness with areflexia, often preceded by a triggering event such as an infection or vaccination. The electrophysiological changes described (prolonged latencies and absent SNAPs) correlate with the demyelinating process causing conduction slowing. These findings are critical when the clinical picture raises suspicion of GBS in the early stages. The differential diagnosis includes acute myelopathies, metabolic neuropathies, and other causes of acute weakness (e.g., tick paralysis, poliomyelitis). Electrophysiological studies, together with cerebrospinal fluid analysis (demonstrating albuminocytologic dissociation), are used to differentiate GBS from these conditions. Management is centered on supportive care and immunomodulation. First-line therapies are intravenous immunoglobulin (IVIG) and plasmapheresis, which have comparable efficacy. Corticosteroids have not been proven beneficial. These treatments are also considered safe during pregnancy and lactation, with IVIG being the preferred modality due to its favorable safety profile. Option (a) is incorrect because normal latencies and amplitudes are not expected in GBS; early demyelination should produce prolonged latencies. Option (b) is correct as it reflects prolonged latency (due to demyelination), with preserved CMAPs (indicating early axonal preservation) and absent SNAPs (reflecting sensory fiber involvement). Option (c) is incomplete because mentioning decreased recruitment or late reflexes alone does not capture the essential early electrophysiological signature. Other options (if any) do not match the early demyelinating pattern seen in GBS. 1. Early electrophysiological studies in GBS may reveal prolonged distal latencies before significant axonal loss occurs. 2. Prompt initiation of IVIG or plasmapheresis can improve outcomes. 3. CSF analysis showing albuminocytologic dissociation supports the diagnosis after the first week. Recent guidelines continue to support early electrodiagnostic testing and the use of IVIG or plasmapheresis as first-line treatments. Ongoing research is exploring biomarkers to predict disease severity and response to therapy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "CMT2a what to expect",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot\u2013Marie\u2013Tooth (CMT) disease encompasses inherited peripheral neuropathies. CMT2A in particular is an axonal subtype frequently caused by mutations in the mitofusin-2 (MFN2) gene, which is critical for mitochondrial dynamics in neurons. The MFN2 mutation disrupts normal mitochondrial fusion and transport along axons, leading to axonal degeneration. Although many forms of CMT show a length-dependent pattern (typically involving the lower limbs), CMT2A can present with a relatively earlier or more pronounced involvement of the upper limbs. Patients with CMT2A often develop distal muscle weakness, sensory deficits, and may exhibit hand muscle atrophy earlier than seen in other CMT subtypes. This unusual pattern of upper limb predominance helps differentiate CMT2A from other hereditary neuropathies where a 'stocking-glove' distribution is more common. Diagnosis is based on clinical findings, nerve conduction studies (which show an axonal pattern with reduced amplitudes but preserved conduction velocities), and confirmatory genetic testing for MFN2 mutations. Differential diagnoses include other inherited neuropathies and acquired axonal neuropathies. There is no curative treatment; management is supportive and focused on physical therapy, occupational therapy, and orthopedic interventions (such as bracing) to maintain mobility and function. Genetic counseling plays an important role. These approaches remain consistent in pregnancy and lactation, with care tailored to symptomatic relief and functional support. Option (a) is correct as the atypical feature of CMT2A is the relatively greater involvement of upper limbs compared to lower limbs, distinguishing it from other CMT subtypes. Option (b) is incorrect because 'loss of snaps' is not a recognized clinical sign in peripheral neuropathy or CMT. 1. CMT2A should be suspected in patients with prominent distal upper limb weakness and hand atrophy. 2. Electrophysiology typically reveals an axonal neuropathy with reduced amplitudes. 3. Genetic confirmation is key for precise diagnosis and counseling. Recent research underscores the role of mitochondrial dynamics in the pathogenesis of CMT2A, and emerging therapeutic strategies are aimed at modulating mitochondrial function. However, current treatment remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has fracture in the acetabulum and noticed numbness on the dorsum of the foot, with weak dorsiflexion where is the lesion",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "The sciatic nerve divides into two main branches: the tibial nerve and the common peroneal (fibular) nerve. The common peroneal nerve, which arises from the lateral division of the sciatic nerve, is primarily responsible for dorsiflexion of the foot and sensation on the dorsum (top) of the foot. In traumatic injuries such as a fracture of the acetabulum, the lateral fibers of the sciatic nerve (destined to form the common peroneal nerve) may be particularly vulnerable. Damage here impairs the nerve's ability to innervate dorsiflexor muscles, leading to foot drop and sensory deficits over the dorsal aspect of the foot. The patient\u2019s presentation of numbness along the dorsum of the foot coupled with weak dorsiflexion directly correlates with an injury to the fibers that constitute the common peroneal nerve. A lesion at the lateral aspect of the sciatic nerve will produce these specific deficits. The differential diagnosis includes L5 radiculopathy and isolated lesions of the common peroneal nerve at other anatomical sites (e.g., at the fibular neck). Detailed neurological examination, imaging (such as CT or MRI for fracture evaluation), and nerve conduction studies help distinguish a nerve branch lesion from a more proximal sciatic trunk or radicular injury. Management involves addressing the underlying fracture with appropriate orthopedic intervention, which may include surgical repair. For the nerve injury, supportive care, physical therapy, and splinting for foot drop are indicated. In pregnant or lactating patients, any surgical and anesthetic interventions should follow established protocols to minimize fetal or neonatal risks. Option (a) 'Lateral aspect of the sciatic nerve' is correct because this area contains the fibers forming the common peroneal nerve. Option (b) 'Medial aspect of the sciatic nerve' relates to tibial nerve function, which would affect plantarflexion and sensation on the sole. Option (c) 'Sciatic trunk' would likely cause a broader deficit affecting both tibial and peroneal distributions rather than an isolated dorsiflexion weakness. Option (d) is not applicable. 1. Foot drop with dorsal foot sensory loss is highly suggestive of common peroneal nerve involvement. 2. Precise anatomical localization of nerve injury is critical in fracture-related trauma. 3. Early intervention with physical therapy can help maximize recovery. Recent studies emphasize the importance of early neuroimaging and electrodiagnostic workup in pelvic fractures to assess associated nerve injuries. Timely surgical management and rehabilitation strategies have been shown to improve long-term functional outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Back pain, L5 radiculopathy, muscle involved",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "mphasizes gluteus medius weakness as a classical sign of L5 radiculopathy. Other options involving muscles with primary innervation from L4 or S1 would be inconsistent with an isolated L5 radiculopathy.",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "L5 radiculopathy involves compression or irritation of the L5 nerve root. Muscles innervated by this root include several key groups but notably the gluteus medius, which is responsible for hip abduction and stabilization. Mechanical compression (often from a lumbar disc herniation or degenerative spondylosis) affecting the L5 nerve root can lead to dysfunction in muscles within its myotomal distribution. The gluteus medius is a primary muscle affected, and its weakness manifests clinically as difficulty with hip abduction and an abnormal gait (e.g., a Trendelenburg gait). Patients with L5 radiculopathy often report lower back pain radiating to the lateral aspect of the hip and leg, along with specific muscle weakness. In this context, weakness in the gluteus medius is a key finding and helps localize the lesion to the L5 nerve root. The differential diagnosis includes radiculopathies at other lumbar levels (such as L4 or S1), hip pathology, and peripheral nerve entrapments. Diagnosis is supported by clinical examination findings, imaging (MRI), and electrodiagnostic studies which localize the affected nerve root. Initial management of L5 radiculopathy is conservative, including physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and possibly epidural steroid injections. Surgical intervention may be considered if conservative measures fail or if there is significant motor deficit. In pregnant or lactating patients, treatment is tailored to minimize exposure to medications that might affect the fetus or nursing infant, with physical therapy playing an especially important role. Option (a) 'Gluteus medius' is correct because it is predominantly innervated by the L5 nerve root via the superior gluteal nerve. Although other muscles such as the tibialis anterior may also be involved, the provided option emphasizes gluteus medius weakness as a classical sign of L5 radiculopathy. Other options involving muscles with primary innervation from L4 or S1 would be inconsistent with an isolated L5 radiculopathy. 1. A Trendelenburg sign may be present in L5 radiculopathy due to gluteus medius weakness. 2. L5 radiculopathy often presents with lateral hip or leg pain. 3. Conservative management is typically the initial approach, with surgical options reserved for refractory cases. Current clinical guidelines endorse a conservative approach for radiculopathy initially, with surgery indicated only in cases with severe or progressive neurologic deficits. There is robust support for multidisciplinary management, including physical therapy and appropriate medical management, in both the general population and in special populations such as pregnant patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about MMN, severe weakness no atrophy asking about dx, but no ncs finding",
    "option_a": ") is correct because the diagnosis of MMN necessitates electrophysiological evidence of conduction block. Options that might suggest a diagnosis of Motor Neuron Disease (MND), CIDP, or ALS are incorrect. MND (or ALS) typically exhibits denervation with marked atrophy, CIDP involves sensory deficits, and ALS shows combined UMN/LMN signs\u2014all contrasting with the scenario of severe weakness without conduction block.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Multifocal Motor Neuropathy (MMN) is an immune\u2010mediated neuropathy that predominantly affects motor nerves. A key diagnostic feature is the presence of conduction block on nerve conduction studies (NCS), which differentiates MMN from other neuropathies that may present with weakness. In this scenario, the absence of conduction block raises serious doubts about an MMN diagnosis, leading to the answer 'None' being correct. MMN is believed to be mediated by an autoimmune process that targets peripheral motor neurons. Demyelination occurs in focal segments of affected motor nerves, resulting in conduction block. Without this electrophysiological evidence, the underlying immune\u2010mediated demyelination cannot be confirmed. Recent studies have demonstrated that anti\u2010GM1 antibodies may be present in many cases, further supporting the autoimmune nature of the disorder. Patients with MMN typically exhibit asymmetric limb weakness with minimal or no muscle atrophy, and the disease spares sensory modalities. The detection of conduction block on NCS is crucial. In our case, despite severe weakness, the absence of conduction block makes the diagnosis of MMN unlikely, and alternative diagnoses (e.g., motor neuron disease) must be considered. The diagnostic workup for MMN includes detailed clinical evaluation, nerve conduction studies (to detect conduction block), and possibly serological testing for anti-GM1 antibodies. Differential diagnoses include Amyotrophic Lateral Sclerosis (ALS), which shows both upper and lower motor neuron signs but lacks conduction block, and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), which usually has sensory involvement. The emphasis on electrophysiological testing is paramount. First\u2010line treatment for confirmed MMN is high\u2010dose intravenous immunoglobulin (IVIg). Other options like immunosuppressants or plasmapheresis have been explored as second\u2010line therapies. In women who are pregnant or lactating, IVIg is generally considered safe and remains the treatment of choice should MMN be diagnosed. However, in cases where the electrophysiological confirmation is lacking (i.e., absence of conduction block), clinicians must reconsider the diagnosis before initiating therapy. Option 'None' (assumed to be listed as Option A) is correct because the diagnosis of MMN necessitates electrophysiological evidence of conduction block. Options that might suggest a diagnosis of Motor Neuron Disease (MND), CIDP, or ALS are incorrect. MND (or ALS) typically exhibits denervation with marked atrophy, CIDP involves sensory deficits, and ALS shows combined UMN/LMN signs\u2014all contrasting with the scenario of severe weakness without conduction block. 1. Conduction block on nerve conduction studies is the hallmark of MMN and its absence should prompt evaluation for alternative diagnoses. 2. MMN is predominantly motor with minimal sensory involvement and typically lacks significant muscle atrophy early in the disease. 3. Always correlate clinical findings with electrophysiological data to avoid diagnostic pitfalls. Recent studies continue to underscore the necessity of electrophysiological confirmation for MMN diagnosis, with guidelines recommending IVIg in patients with confirmed conduction block. The presence of anti-GM1 antibodies further supports the autoimmune basis of MMN, although their absence does not exclude the diagnosis if conduction block is present.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the most common polio presentation",
    "option_a": "(Asymptomatic) is correct because epidemiologic data show the majority of polio infections produce no clinical symptoms. Options b (Meningitis), c (Flu",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Poliovirus infection spans a wide clinical spectrum. The majority of infections do not lead to clinical illness, as the immune system often contains the virus before significant neuronal involvement occurs. Following infection, poliovirus replicates in the oropharyngeal and intestinal mucosa. In most individuals, the immune response neutralizes the virus before it penetrates the central nervous system. Only in a very small proportion of cases does the virus invade motor neurons, leading to paralytic poliomyelitis. Approximately 72% of poliovirus infections are asymptomatic, making subclinical infection the most common presentation. In symptomatic cases, presentations range from minor flu\u2010like illness (abortive poliomyelitis) to aseptic meningitis (non\u2010paralytic poliomyelitis) and, rarely, to paralytic disease (<1%). This epidemiological fact is critical in understanding the natural history of poliomyelitis. Diagnosis in polio primarily relies on clinical features and cerebrospinal fluid (CSF) analysis (showing lymphocytic pleocytosis in meningitic forms). The differential includes other viral meningitides and acute flaccid paralysis due to other causes (e.g., Guillain\u2013Barr\u00e9 syndrome). Epidemiologic context and immunization history remain essential components of the evaluation. Poliomyelitis is managed through prevention with vaccination rather than specific antiviral treatment. The inactivated polio vaccine (IPV) is recommended, especially in pregnant women, because it contains no live virus. Supportive care is provided in cases of paralytic disease. For lactating mothers, IPV is similarly safe with no risk to the infant. Option a (Asymptomatic) is correct because epidemiologic data show the majority of polio infections produce no clinical symptoms. Options b (Meningitis), c (Flu-like illness), and d (Flaccid weakness) are less common presentations, seen in decreasing order of frequency and severity. 1. Approximately 70% or more of poliovirus infections are asymptomatic, a fact that underpins the virus's silent spread. 2. Paralytic poliomyelitis, while clinically dramatic, occurs in less than 1% of infections. 3. Preventative vaccination remains the cornerstone of polio control. Current research and global vaccination campaigns continue to support the epidemiologic data regarding polio\u2019s presentation. Updated guidelines reinforce the use of IPV, particularly in pregnant and lactating populations, emphasizing safety and efficacy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Recurrent falls and abnormal Brain MRI with history of male affected in the family dx",
    "option_a": "(Adrenomyeloneuropathy) is correct based on the combination of clinical features (recurrent falls, spastic paraparesis), MRI findings, family history, and confirmatory biochemical/genetic tests. Other conditions like hereditary spastic paraplegia and multiple sclerosis would not present with the same biochemical pattern (elevated VLCFA) or clear X",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Adrenomyeloneuropathy (AMN) is a phenotype within the spectrum of X-linked adrenoleukodystrophy (ALD). It generally presents in adulthood, particularly in males, with slowly progressive spastic paraparesis and signs of peripheral neuropathy. Mutations in the ABCD1 gene impair the peroxisomal beta-oxidation of very long-chain fatty acids (VLCFA), leading to their accumulation. This accumulation causes progressive demyelination, axonal degeneration, and adrenal insufficiency. The characteristic MRI findings with white matter changes support the diagnosis. AMN typically presents with recurrent falls, gait disturbances due to spastic paraparesis, and sometimes peripheral neuropathy. A family history of similar symptoms in males, consistent with the X-linked inheritance pattern, further supports this diagnosis. Biochemical findings (elevated VLCFA levels) and the identification of an ABCD1 mutation are confirmatory. The evaluation of suspected AMN includes brain and spinal cord MRI, measurement of serum VLCFA levels, and genetic testing for mutations in the ABCD1 gene. Differential diagnoses include hereditary spastic paraplegias (which usually lack adrenal involvement), multiple sclerosis (with a relapsing-remitting course and inflammatory markers), and vitamin B12 deficiency neuropathy. A comprehensive assessment combining clinical, imaging, and laboratory findings is needed. Management of AMN is primarily supportive. First-line strategies include physical therapy, spasticity management, and adrenal hormone replacement if adrenal insufficiency is present. Emerging therapies such as Lorenzo\u2019s oil and hematopoietic stem cell transplantation have limited roles, primarily in early cerebral forms. For pregnant or lactating women (in cases of female carriers manifesting mild symptoms), careful endocrine management and multidisciplinary follow-up are recommended. Genetic counseling is key given the X-linked inheritance. Option a (Adrenomyeloneuropathy) is correct based on the combination of clinical features (recurrent falls, spastic paraparesis), MRI findings, family history, and confirmatory biochemical/genetic tests. Other conditions like hereditary spastic paraplegia and multiple sclerosis would not present with the same biochemical pattern (elevated VLCFA) or clear X-linked inheritance. 1. AMN is the adult-onset variant of X-linked adrenoleukodystrophy, marked by progressive spastic paraparesis and peripheral neuropathy. 2. Elevated VLCFA levels and ABCD1 mutations are key diagnostic markers. 3. Family history, especially in males, is a critical clue to its X-linked inheritance. Recent research reinforces the importance of early biochemical screening (VLCFA levels) and genetic testing for ABCD1 mutations. Although treatment options remain mostly supportive, ongoing trials exploring gene therapy and novel metabolic modulators offer hope for future interventions.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_30.png"
  },
  {
    "question": "Male with sensory motor axonal neuropathy, decrease pain, temp, and vibration, family hx",
    "option_a": "(RET) is incorrect as RET mutations are linked with conditions like medullary thyroid carcinoma and Hirschsprung disease, not HSAN. Option b (SPTLC) is correct because mutations in SPTLC genes are known causes of HSAN type I. Options c (TRKA) and d (IKAP) are linked to HSAN IV and familial dysautonomia (HSAN III), respectively, which have distinct clinical features not matching the case described.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary Sensory and Autonomic Neuropathies (HSANs) are a group of genetic disorders characterized by progressive loss of sensory and sometimes autonomic function. HSAN type I, in particular, is usually associated with mutations in the SPTLC genes. Mutations in the SPTLC1 and SPTLC2 genes affect the enzyme serine palmitoyltransferase, leading to abnormal sphingolipid metabolism. This disrupts normal neuronal function and structure, causing a predominantly sensory and some motor axonal neuropathy. The resulting degeneration leads to impaired pain, temperature, and vibration sensation. Patients typically present with a sensory-motor axonal neuropathy affecting pain, temperature, and vibration sense. The family history and age of onset help distinguish HSAN type I from other hereditary neuropathies. Unlike congenital insensitivity to pain (caused by NTRK1 mutations) or familial dysautonomia (related to ELP1 mutations), HSAN type I due to SPTLC mutations usually has a later onset and a milder autonomic involvement. Confirmatory diagnosis is achieved through genetic testing for SPTLC gene mutations. Differential diagnoses include HSAN types IV and III, associated with TRKA (NTRK1) and IKAP (ELP1) mutations respectively, which have different clinical presentations and inheritance patterns. Electrophysiological studies typically reveal an axonal neuropathy pattern. Currently, treatment is supportive, focusing on pain management, physical therapy, and prevention of injuries due to loss of sensation. There is no definitive cure. In pregnant and lactating women with HSAN type I, management is symptomatic, and any pharmacological therapy (e.g., pain modulators) must be chosen carefully considering fetal and neonatal safety. Genetic counseling is important due to its hereditary nature. Option a (RET) is incorrect as RET mutations are linked with conditions like medullary thyroid carcinoma and Hirschsprung disease, not HSAN. Option b (SPTLC) is correct because mutations in SPTLC genes are known causes of HSAN type I. Options c (TRKA) and d (IKAP) are linked to HSAN IV and familial dysautonomia (HSAN III), respectively, which have distinct clinical features not matching the case described. 1. In HSAN type I, the SPTLC gene mutation leads to a predominantly sensory axonal neuropathy with some motor involvement. 2. Always correlate genetic findings with clinical symptoms and family history for accurate diagnosis. 3. Differentiation from other HSAN subtypes is crucial as it influences genetic counseling and management. Genetic testing has become the cornerstone for diagnosing HSAN. Recent studies have refined our understanding of the clinical spectrum associated with SPTLC mutations and are investigating potential therapies aimed at modifying sphingolipid metabolism. Current guidelines emphasize a supportive approach with careful consideration for safety in pregnant and lactating patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "A 20s-year-old female who presented to the clinic with history of progressive bilateral upper limb decrease pain sensation, with no weakness. Examination significant for decrease pinprick sensation bilaterally over upper limbs. Intact motor and vibration sensation.\nWhat is the most likely diagnosis?",
    "option_a": "Syringomyelia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Syringomyelia is a disorder in which a fluid\u2010filled cavity (syrinx) forms within the spinal cord, typically centered in the cervical region. It characteristically causes a \u201ccape\u2010like\u201d bilateral loss of pain and temperature sensation in the upper extremities due to selective involvement of decussating fibers in the anterior white commissure. The formation of the syrinx expands within the central spinal cord, compressing the crossing fibers of the spinothalamic tract that mediate pain and temperature sensation. Because the dorsal columns (vibration and proprioception) and lateral corticospinal tracts (motor) are situated more peripherally, they remain relatively intact in early disease, explaining the dissociated sensory loss. Patients typically present with a bilateral loss of pain and temperature sensation in a \u201ccape distribution\u201d affecting the upper extremities. In this case, the patient\u2019s progressive decrease in pinprick sensation in the upper limbs without motor weakness or dorsal column involvement fits the classical presentation of syringomyelia. The differential includes central cord syndrome (often post-traumatic), demyelinating processes like MS, and peripheral neuropathies. MRI of the cervical spine is the diagnostic modality of choice to visualize the syrinx. Additional studies may be needed to evaluate associated conditions such as Chiari I malformation. Management is tailored to the severity and progression of symptoms. First-line management for symptomatic lesions often involves neurosurgical decompression (such as posterior fossa decompression in cases of Chiari malformation) and drainage of the syrinx. In less aggressive cases, observation and symptomatic management may be appropriate. In pregnant or lactating patients, careful multidisciplinary evaluation is essential to balance surgical risks with neurological progression, and timing of surgical intervention may be adjusted accordingly. Option A (Syringomyelia) directly correlates with the clinical presentation described. The other options were not provided, but based on the clinical scenario, alternative diagnoses such as peripheral neuropathies or a central cord syndrome would not account for the selective pattern of sensory loss without motor or dorsal column deficits. 1. Syringomyelia typically presents with a bilateral loss of pain and temperature sensation in a cape-like distribution. 2. Preservation of motor strength and vibration sense is due to the anatomical location of the affected fibers in the spinal cord. Recent advances in neuroimaging have reinforced the role of high-resolution MRI in early diagnosis of syringomyelia. Surgical decompression remains the mainstay of treatment for progressive cases, with ongoing research into less invasive techniques and improved patient selection criteria.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A Patient presented the outpatient clinic with complain of wrist drop. Examination showed weakness in finger extension, with deviation. Normal wrist and elbow flexion and extension. Normal sensation.\nWhere is the site of the lesion?",
    "option_a": "Radial nerve at axillary area",
    "option_b": "Radial nerve at spiral groove",
    "option_c": "Posterior interosseous nerve.",
    "option_d": "Brachial plexus",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The posterior interosseous nerve (PIN) is a purely motor branch of the radial nerve that supplies most of the extensor muscles of the forearm. It is responsible for finger and thumb extension. Lesions of the PIN result in isolated motor deficits affecting finger extension, while sparing the sensory distribution of the radial nerve because the sensory fibers travel in the superficial branch. Compression or entrapment of the PIN leads to failure of motor signal transmission to the extensor muscles without accompanying sensory loss. The patient demonstrates weakness in finger extension with preserved wrist and elbow movements and intact sensation. This dissociation is typical of a posterior interosseous nerve syndrome, as lesions higher in the radial nerve would affect both motor and sensory components. Differential diagnoses include a high radial nerve injury (e.g., at the spiral groove), which would present with additional sensory deficits, and brachial plexus injuries which would have a wider range of motor and sensory involvement. Electromyography (EMG) and nerve conduction studies are useful in pinpointing the lesion to the PIN. Initial management involves conservative measures such as rest, anti-inflammatory medications, and physical therapy. If symptoms persist or worsen, surgical decompression may be considered. In pregnant or lactating patients, conservative treatment is preferred to avoid surgical risks unless absolutely necessary. Option A (Radial nerve at the axillary area) would typically produce a more extensive motor and sensory deficit. Option B (Radial nerve at the spiral groove) usually presents with sensory loss and wrist drop. Option C (Posterior interosseous nerve) correctly describes an isolated motor deficit in finger extension with intact sensation. Option D (Brachial plexus) would involve multiple nerve territories and not the isolated PIN distribution. 1. A pure motor deficit in the distribution of the radial nerve often indicates a lesion of the posterior interosseous nerve. 2. Normal sensory exam with motor weakness is a key clue to differentiate PIN syndrome from more proximal radial nerve injuries. Recent literature supports the use of electrodiagnostic studies and ultrasonography for precise localization of PIN lesions, and conservative management remains first-line therapy except in cases of persistent or refractory symptoms.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient post hip replacement surgery presenting with right lower limb weakness. Examination showed hip flexion and extension 5/5, foot dorsal flexion 0/5, plantarflexion 3/5 with sensory loss of lateral leg.\nEMG/NCS showed involvement of anterior tibial, gastrocnemius and short head of bicep femoris.\nWhat is the most likely injured nerve?",
    "option_a": "Tibial nerve",
    "option_b": "Peroneal nerve",
    "option_c": "Sciatic nerve",
    "option_d": "Femoral nerve",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The sciatic nerve is the largest nerve in the human body, comprised of the tibial and common peroneal (fibular) components. It innervates the muscles of the posterior thigh and most of the lower leg and foot. Injury to the sciatic nerve, particularly during procedures like hip replacement surgery, can occur due to stretch, compression, or inadvertent transection. This injury typically affects both the tibial and peroneal divisions, leading to a mixture of deficits in motor control and sensation. The patient exhibits a significant weakness in foot dorsiflexion (0/5), moderate weakness in plantar flexion (3/5), and sensory loss over the lateral leg. The involvement of muscles innervated by both the tibial (gastrocnemius) and the common peroneal (anterior tibialis and short head of the biceps femoris) divisions indicates a lesion affecting the sciatic nerve before its bifurcation. Differentials include isolated peroneal nerve injury (which would not affect plantar flexion or the gastrocnemius) or isolated tibial nerve injury. Nerve conduction studies and EMG are essential to determine the extent and localization of nerve involvement, and imaging may be used to assess for mechanical causes post-surgery. Management primarily involves supportive care, including physical therapy and orthotic devices to manage foot drop. In cases where recovery is delayed, surgical exploration may be considered. In pregnant or lactating patients, non-operative management is generally favored to minimize additional risks. Option A (Tibial nerve) is incorrect because an isolated tibial nerve injury would not account for the involvement of the anterior tibial muscle or the short head of the biceps femoris. Option B (Peroneal nerve) is also insufficient as it would not affect the gastrocnemius. Option C (Sciatic nerve) correctly explains the combined muscle involvement and sensory loss. Option D (Femoral nerve) is unrelated as it primarily supplies the anterior thigh and does not affect lower leg dorsiflexion. 1. Hip replacement surgery carries a known risk of sciatic nerve injury, necessitating careful intraoperative nerve protection. 2. Combined deficits in both the tibial and peroneal distributions point toward a sciatic nerve lesion rather than an isolated branch injury. Contemporary studies highlight the role of intraoperative nerve monitoring during hip replacement to mitigate risks. Recovery outcomes improve with early physical therapy and timely recognition of nerve injury, with EMG studies being central to the diagnosis.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with typical features of myasthenia gravis. ACHR antibody and Anti MUSK are negative.\nWhat lab investigation to send next to confirm the diagnosis?",
    "option_a": "P/Q CA",
    "option_b": "Ca",
    "option_c": "Na",
    "option_d": "LRP4",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia gravis (MG) is an autoimmune disorder characterized by antibodies targeting components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). In typical MG, antibodies cause reduced receptor availability or impaired neuromuscular transmission, leading to fluctuating muscle weakness. However, a subset of patients are seronegative for both AChR and MuSK antibodies. In these cases, antibodies against low-density lipoprotein receptor-related protein 4 (LRP4) have been identified, which interfere with the clustering of AChRs at the neuromuscular junction. Patients with MG typically present with fatigable muscle weakness, often affecting the ocular, facial, and bulbar muscles. When standard antibodies (AChR and MuSK) are negative, testing for anti-LRP4 antibodies is indicated to confirm the diagnosis. Differential diagnoses include Lambert-Eaton myasthenic syndrome (often associated with voltage-gated calcium channel antibodies), congenital myasthenic syndromes, and botulism. Electrophysiological tests such as repetitive nerve stimulation and single-fiber EMG, along with specific antibody assays, assist in the diagnosis. First-line treatment for MG includes acetylcholinesterase inhibitors, such as pyridostigmine. Immunosuppressive therapy (e.g., corticosteroids, azathioprine) is often added for more severe or refractory cases. Thymectomy is considered for appropriate patients. During pregnancy and lactation, pyridostigmine is generally considered safe, but immunosuppressant usage requires caution and multidisciplinary consultation. Option A (P/Q CA) typically pertains to Lambert-Eaton myasthenic syndrome and is not relevant in seronegative MG. Option B (Ca) and Option C (Na) are irrelevant tests for MG evaluation. Option D (LRP4) is the correct investigation to further evaluate a patient with clinical MG features who is seronegative for AChR and MuSK antibodies. 1. Approximately 10-15% of patients with myasthenia gravis are seronegative for both AChR and MuSK antibodies; in these cases, anti-LRP4 antibodies can be diagnostic. 2. The detection of anti-LRP4 antibodies helps differentiate seronegative MG from other neuromuscular junction disorders. Recent research supports the clinical relevance of anti-LRP4 antibodies in the diagnostic work-up of seronegative myasthenia gravis. Updated guidelines recommend that patients with typical MG symptoms and negative routine antibody tests should be evaluated for LRP4 antibodies, which has improved diagnostic accuracy in this subgroup.",
    "exam_year": "2023",
    "exam_type": "Part I"
  }
]